RenovoRx announces USD 10 million private placement of common stock and warrants

Reuters03-18 20:35
RenovoRx announces USD 10 million private placement of common stock and warrants

RenovoRx announced a private placement of common stock and milestone warrants expected to raise about USD 10 million in gross proceeds. The company said it signed definitive purchase agreements with institutional investors and expects the financing to close on March 20, 2026. RenovoRx plans to issue about 10.64 million shares at USD 0.94 per share, along with milestone-based warrants for about 5.32 million shares. The milestone warrants have an exercise price of USD 1.75 per share and expire on the earlier of March 30, 2029 or 30 days after RenovoRx reports a fiscal quarter with USD 1.5 million in gross product revenue. RenovoRx said the securities have not been registered under the Securities Act of 1933.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603180835PRIMZONEFULLFEED9674383) on March 18, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment